Evidence map›Paper›PMID 38844800›Full record

ArticleNPJ breast cancer2024

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A Hurvitz, Joyce O'Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A Carey and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Hope S RugoDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Hope.Rugo@ucsf.edu.ORCID http://orcid.org/0000-0001-6710-4814
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Delphine LoiratDepartment of Medical Oncology and D3i, Institut Curie, Paris, France.
Kevin PunieDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1162-7963
Aditya BardiaDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4885-1157
Sara A HurvitzMedical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7808-7191
Joyce O'ShaughnessyBaylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
Javier CortésInternational Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7623-1583
Véronique DiérasDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.ORCID http://orcid.org/0000-0001-8094-4738
Lisa A CareyDepartment of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-2388-4649
Luca GianniGianni Bonadonna Foundation, Milano, Italy.ORCID http://orcid.org/0000-0002-2372-9625
Martine J PiccartMedical Oncology, Institute Jules Bordet, Brussels, Belgium.
Sibylle LoiblDepartment of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.
David M GoldenbergDepartment of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
Quan HongDepartment of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
Martin OlivoDepartment of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
Loretta M ItriDepartment of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
Kevin KalinskyColumbia University Irving Medical Center, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38844800
PMCPMC11156627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.